Yanan Zhu
Stock Analyst at Wells Fargo
(4.51)
# 304
Out of 5,022 analysts
80
Total ratings
60%
Success rate
20.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Overweight | $65 → $80 | $58.94 | +35.73% | 4 | Oct 2, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $3.59 | +11.58% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $37.88 | +18.80% | 1 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $82 | $71.46 | +14.75% | 3 | Aug 22, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $16 → $12 | $2.93 | +309.56% | 4 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $5.16 | +55.04% | 3 | Aug 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $4 → $2.5 | $1.50 | +67.22% | 4 | Aug 13, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $6 → $5 | $1.62 | +209.60% | 4 | Aug 13, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $42 | $21.34 | +96.81% | 8 | Aug 12, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $38 | $25.42 | +49.52% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $2.12 | +560.38% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $24.00 | +87.54% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $75 | $48.23 | +55.50% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $50 | $21.45 | +133.10% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $1 | $0.16 | +527.35% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $25.43 | +175.27% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.98 | +101.01% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $21.00 | +90.48% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $69.38 | -6.31% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.82 | +240.14% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.68 | +485.91% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.49 | +12,793.98% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $804.49 | -59.48% | 1 | Feb 2, 2021 |
uniQure
Oct 2, 2025
Maintains: Overweight
Price Target: $65 → $80
Current: $58.94
Upside: +35.73%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $3.59
Upside: +11.58%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $37.88
Upside: +18.80%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $77 → $82
Current: $71.46
Upside: +14.75%
Metagenomi
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.93
Upside: +309.56%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $5.16
Upside: +55.04%
Fate Therapeutics
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.50
Upside: +67.22%
Autolus Therapeutics
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.62
Upside: +209.60%
Arcturus Therapeutics Holdings
Aug 12, 2025
Maintains: Overweight
Price Target: $45 → $42
Current: $21.34
Upside: +96.81%
RAPT Therapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $51 → $38
Current: $25.42
Upside: +49.52%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.12
Upside: +560.38%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $24.00
Upside: +87.54%
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $48.23
Upside: +55.50%
Aug 7, 2025
Maintains: Overweight
Price Target: $48 → $50
Current: $21.45
Upside: +133.10%
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.16
Upside: +527.35%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $25.43
Upside: +175.27%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.98
Upside: +101.01%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $21.00
Upside: +90.48%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $69.38
Upside: -6.31%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $8.82
Upside: +240.14%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.68
Upside: +485.91%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.49
Upside: +12,793.98%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $804.49
Upside: -59.48%